Patents related to therapeutic activation of KATP and K 2P potassium channels for neuroprotection: Ischemic/hypoxic/anoxic injury and general anesthetics

Expert Opinion on Therapeutic Patents

Volumn 19, Issue 4, 2009, Pages 433-460

  Judge, Susan I V ^a,b   Smith, Paul J ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

Author keywords

ATP sensitive potassium channels; Ischemia; K2P; KATP; Local anesthetics; Neuroprotection; Tandem two pore potassium channels

Indexed keywords

[[4 (1,4,5,6 TETRAHYDRO 4 METHYL 6 OXO 3 PYRIDAZINYL)PHENYL]HYDRAZONO]PROPANEDINITRITE; [[4 (3,6 DIHYDRO 6 METHYL 2 OXO 2H 1,3,4 THIADIAZIN 5 YL)PHENYL]HYDRAZONO]PROPANEDINITRILE; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ANTIINFLAMMATORY AGENT; APRIKALIM; BENZOPYRAN DERIVATIVE; BENZOTHIADIAZINE DERIVATIVE; BENZOTHIAZINE 1,1 DIOXIDE; BU 4726 G A; BU 4726 G B; COUMARIN DERIVATIVE; CROMAKALIM; DIAZOXIDE; GLIBENCLAMIDE; GUANIDINE DERIVATIVE; HALOTHANE; IPTAKALIM; K2P POTASSIUM CHANNEL; NICORANDIL; PINACIDIL; POTASSIUM CHANNEL; PYRIDINE DERIVATIVE; QUINOLINE DERIVATIVE; SEVOFLURANE; SULFONYLUREA; THIAZINE DERIVATIVE; TOLBUTAMIDE; UNCLASSIFIED DRUG; UREA DERIVATIVE;

AMINO ACID SEQUENCE; BRAIN HYPOXIA; BRAIN INJURY; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; DIABETES MELLITUS; DRUG EFFECT; DRUG STRUCTURE; EPILEPSY; GENERAL ANESTHESIA; GLUCOSE HOMEOSTASIS; HEADACHE; HEART PROTECTION; HEMORRHAGIC SHOCK; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIA; LOCAL ANESTHESIA; MIGRAINE; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; OVERACTIVE BLADDER; PATENT; REVIEW; SEIZURE; SEXUAL DYSFUNCTION; STROKE; TRANSGENIC ANIMAL;

ANESTHETICS, GENERAL; ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; HYPOXIA-ISCHEMIA, BRAIN; KATP CHANNELS; NEUROPROTECTIVE AGENTS; PATENTS AS TOPIC; POTASSIUM CHANNELS, TANDEM PORE DOMAIN;

EID: 67649621723     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543770902765151     Document Type: Review

References (210)

1. Alexander SPH, Mathie A, Peters JA. Guide to receptors and channels (GRAC). Third edition. Br J Pharmacol 2008;153(Suppl 2):S1-S209
2. Judge SIV, Smith PJ, Stewart PE, Bever CT. Potassium channel blockers and openers as CNS neurologic therapeutic agents. Rec Patents CNS Drug Discov 2007;2:200-228 (Pubitemid 350200292)
3. Judge SIV, Bever CT Jr. Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther 2006;111:224-259 (Pubitemid 43765538)
4. Gutman GA, Chandy KG, Grissmer S, et al. International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol Rev 2005;57:473-508
5. Wei AD, Gutman GA, Aldrich R, et al. International Union of Pharmacology. LII. Nomenclature and molecular relationships of calcium-activated potassium channels. Pharmacol Rev 2005;57:463-472
6. Kubo Y, Adelman JP, Clapham DE, Jan LY. International Union of Pharmacology. LIV. Nomenclature and molecular relationships of inwardly rectifying potassium channels. Pharmacol Rev 2005;57:509-526
7. Goldstein SAN, Bayliss DA, Kim D, et al. International Union of Pharmacology. LV. Nomenclature and molecular relationships of two-P potassium channels. Pharmacol Rev 2005;57:527-540
8. Noma A. ATP-regulated K+ channels in cardiac muscle. Nature 1983;305(5930):147-148 (Pubitemid 14235671)
9. Kakei M, Noma A, Shibasaki T. Properties of adenosine-triphosphate- regulated potassium channels. J Physiol (Lond) 1985;363:441-462
10. Noma A, Shibasaki T. Membrane current through adenosine-triphosphate- regulated potassium channels in guinea-pig ventricular cells. J Physiol (Lond) 1985;363:441-462 (Pubitemid 15000318)
11. Cook DL, Hales CN. Intracellular ATP directly blocks K+ channels in pancreatic beta-cells. Nature 1984;311(5983):271-273 (Pubitemid 14071146)
12. Ashcroft FM, Harrison DE, Ashcroft SJ. Glucose induces closure of single potassium channels in isolated rat pancreatic beta-cells. Nature 1984;312(5993):446-448 (Pubitemid 15217837)
13. Rorsman P, Trube G. Glucose dependent K+-channels in pancreatic beta-cells are regulated by intracellular ATP. Pflügers Arch 1985;405(4):305-309 (Pubitemid 16202499)
14. Ashford ML, Sturgess NC, Trout NJ, et al. Adenosine-5′- triphosphate-sendsitive ion channels in neonatal rat cultured central neurones. Pflügers Arch 1988;412(3):297-304 (Pubitemid 18196384)
15. Amoroso S, Schmid-Antomarchi H, Fosset M, Lazdunski M. Glucose, sulfonylureas, and neurotransmitter release: role of ATP-sensitive K+ channels. Science 1990;247(4944):852-854 (Pubitemid 20078565)
16. Moreau C, Prost AL, Dérand R, Vivaudou M. SUR, ABC proteins targeted by KATP channel openers. J Mol Cell Cardiol 2005;38(6):951-963 (Pubitemid 40725943)
17. Sturgess NC, Ashford ML, Cook DL, Hales CN. The suphonylurea receptor may be an ATP-sensitive potassium channels. Lancet 1985;2(8453):474-475 (Pubitemid 15013927)
18. Sturgess NC, Kozlowski RZ, Carrington CA, et al. Effects of sulphonylureas and diazoxide on insulin secretion and nucleotide-sensitive channels in an insulin-secreting cell line. Br J Pharmacol 1988;95(1):83-94 (Pubitemid 18225202)
19. Trube G, Rorsman P, Ohno-Shosaku T. Opposite effects of tolbutamide and diazoxide on the ATP-dependent K+ channel in mouse pancreatic beat-cells. Pflügers Arch 1986;407(5):493-499 (Pubitemid 17175041)
20. Dunne MJ, Illot MC, Peterson OH. Interaction of diazoxide, tolbutamide and ATP4- on nucleotide-dependent K+ channels in an insulin-secreting cell line. J Membr Biol 1987;99(3):215-224 (Pubitemid 18046040)
21. Zhu HL, Luo WQ, Wang H. Iptakalim protects against hypoxic brain injury through multiple pathways associated with ATP-sensitive potassium channels. Neuroscience 2008;157:884-894
22. Lapi D, Marchiafava PL, Colantuoni A. Pial microvascular responses to transienet bilateral common carotid artery occlusion: effects of hypertonic glycerol. J Vasc Res 2008;45(2):89-102 (Pubitemid 351651294)
23. Sun XL, Zeng XZ, Zhou F, et al. KATP channel openers facilitate glutamate uptake by GluTs in rat primary cultured astrocytes. Neuropharmacology 2008;33(6):1336-1342
24. Jiang KW, Yu ZS, Shui QX, Xia ZZ. Activation of ATP-sensitive potassium channels prevents the cleavage of cytosolic μ-ccalpain and abrogates the elevation of nuclear c-Fos and c-Jun expressions after hypoxic-ischemia in neonatal rat brain. Mol Brain Res 2005;133(1):87-94 (Pubitemid 40127493)
25. Yuan HB, Huang Y, Zheng S, Zuo Z. Hypothermic preconditioning increases survival of Purkinje neurons in rat cerebellar slices after an in vitro simulated ischemia. Anesthesiology 2004;100(2):331-337 (Pubitemid 38133701)
26. Kis BK, Rajapakse NC, Snipes JA, et al. Diazoxide induces delayed pre-conditioning in cultures rat cortical neurons. J Neurochem 2003;87(4):969-980 (Pubitemid 37444572)
27. Garcia De Arriba S, Franke H, Pissarek M, et al. Neuroprotection by ATP-dependent potassium channels in rat neocortical brain slices during hypoxia. Neurosci Let 1999;273(1):13-16 (Pubitemid 29415691)
28. Riepe MW, Esclaire F, Kasischke K, et al. Increased hypotoxic tolerance by chemical inhibition of oxidative phosphorylation: 'chemical preconditioning'. J Cereb Blood Flow Metab 1997;17(3):257-264
29. Pamenter ME, Shin D SH, Cooray M, Buck LT. Mitochondrial ATP-sensitive K+ channels regulate NMDAR activity in the cortex of the anoxic western painted turtle. J Physiol (Lond) 2008;586(4):1043-1058 (Pubitemid 351267345)
30. Raval AP, Dave KR, DeFrazio RA, Perez-Pinzon MA. EpsilonPKC phosphorylates the mitochondrial K+ATP channel during induction of ischemic preconditioning in the rat hippocampus. Brain Res 2007;1184:345-353 (Pubitemid 350160588)
31. Sun HS, Feng ZP, Miki T, et al. Enhanced neuronal damage after ischemic insults in mice lacking Kir6.2-containing ATP-sensitive K+ channels. J Neurophyiol 2005;95(4):2590-2601
32. Kawamura T, Kadosaki M, Nara N, et al. Nicorandil attenuates NF-κB activation, adhesion molecule expression, and cytokine production in patients with coronary artery bypass surgery. Shock 2005;24(2):103-108 (Pubitemid 41105505)
33. Konstantinov IE, Cheung MM, Shimizu M, et al. Remote ischemic preconditioning of the recipient reduces myocardial ischemia-reperfusion injury of the denervated donor heart via a Katp channel-dependent mechanism. Transplantation 2005;79(12):1691-1695 (Pubitemid 40885266)
34. Kehl F, Payne RS, Toewer N, Schurr A. Seveflurane-induced preconditioning of rat brain in vitro and the role of KATP channels. Brain Res 2004;1021(1):76-81 (Pubitemid 39158659)
35. Bancila V, Nikonenko I, Dunant Y, et al. Zinc inhibits glutamate release via activation of pre-synaptic K channels and reduces ischaemic damage in rat hippocampus. J Neurochem 2004;90(5):1243-1250 (Pubitemid 39167357)
36. Won R, Lim JY, Lee SY, et al. Neuroprotective effect of KR-31378 via KATP channel opening against ischemic insult. Biol Pharm Bull 200427(8):1285-1288
37. Raupach T, Ballanyi K. Intracellular pH and KATP channel activity in dorsal vagal neurons of juvenile rats in situ during metabolic disturbances. Brain Res 2004;1017(1-2):137-145 (Pubitemid 38917153)
38. Yoshida M, Nakakimura K, Cui YJ, et al. Adenosine A(1) receptor antagonist and mitochondrial ATP-sensitive potassium channel blocker attenuate the tolerance to focal cerebral ischemia in rats. J Cereb Blood Flow Metab 2004;24(7):771-779
39. D'Souza SP, Yellon DM, Martin C, et al. B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening. Am J Physiol Heart Circ Physiol 2003;284(5):H1592-600 (Pubitemid 36460771)
40. Caparrekku DJ, Cattaneao SM 2nd, Sethea BT, et al. Pharmacological preconditioning ameliorates neurological injury in a model of spinal cord ischemia. Ann Thorac Surg 2002;74(3):838-844
41. Janigro D, Ngyyen TS, Meno J, et al. Endothelium-dependent regulation of cerebrovascular tone by extracellular and intracellular ATP. Am J Physiol 1997;273(2 Pt 2):H878-85 (Pubitemid 27392244)
42. Nishimura M, Takahashi H, Nanbu A, et al. Cerebral adenosine triphosphate-sensitive K+ channels may be impaired during acute cerebral ischemia in spontaneously hypertensive rats. J Auton Nerv Syst 1996;58(3):139-146 (Pubitemid 26167170)
43. Xie Y, Zacharias E, Hoff P, Tegtmeier F. Ion channel involvement in anoxic depolarization induced by cardiac arrest in rat brain. J Cereb Blood Flow Metab 1995;15(4):587-594
44. Nishimura M, Nanbu A, Sakamoto M, et al. Role of cerebral ATP-sensitive K+ channels in arterial pressure regulation during acute cerebral ischaemia in SHR and WKY rats. Clin Exp Pharmacol Physiol Suppl 1995;22(1):S70-2 (Pubitemid 26062046)
45. Xue J, Zhou D, Yao H, et al. Role of transporters and ion channels in neuronal injury under hypoxia. Am J Physiol Regul Integr Comp Physiol 2007;294(2):R451-7
46. Thompson JW, Prentice HM, Lutz PL. Regulation of extracellular glutamate levels in the long-term anoxic turtle striatum: coordinated activity of glutamate transporters, adenosine, K+ATP channels and GABA. J Biomed Sci 2007;14(6):809-817 (Pubitemid 47573154)
47. Huang L, Li W, Li B, Zou F. Activation of ATP-sensitive K channels protects hippocampal CA1 neurons from hypoxia by suppressing p53 expression. Neurosci Lett 2206;398(1-2):34-38
48. Moon CH, Kim MY, Kim MJ, et al. KR-31378, a novel benzopyran analog, attenuates hypoxia-induced cell death via mitochondrial KATP channel and protein kinase C-epsilon in heart-derived H9c2 cells. Eur J Pharmacol 2004;506(1):27-35 (Pubitemid 39575082)
49. Müller M, Brockhaus J, Ballanyi K. ATP-independent anoxic activation of ATP-sensitive K+ channels in dorsal vagal neurons of juvenile mice in situ. Neuroscience 2002;109(2):313-328 (Pubitemid 34098971)
50. Gyte A, Pritchard LE, Jones HB, et al. Reduced expression of the KATP channel subunit, Kir6.2, is associated with decreased expression of neuropeptide Y and agouti-related protein in the hypothalami of Zucker diabetic fatty acids. J Neuroendocrinol 2007;19(12):941-951 (Pubitemid 350131080)
51. Miki T, Liss B, Minami K, et al. ATP-sensitive K+ channels in the hypothalamus are essential for the maintenance of glucose metabolism. Nat Neurosci 2001;4(5):507-512 (Pubitemid 32397188)
52. Spanswick D, Smith MA, Mirshamsi S, et al. Insulin activates ATP-sensitive K+ channels in hypothalamic neurons of lean, but not obese rats. Nat Neurosci 2000;3(8):757-758 (Pubitemid 30485698)
53. Dunn-Meynell AA, Rawson NE, Levin BE. Distribution and phenotype of neurons containing the ATP-sensitive K+ channel in rat brain. Brain Res 1998;814(1-2):41-54 (Pubitemid 29023410)
54. O'Rourke B. Evidence for mitochondrial K+ channels and their role in cardioprotection. Circ Res 2004;94:420-432 (Pubitemid 38326277)
55. Hanley PJ, Daut J. KATP channels and preconditioning: a re-examination of the role of mitochondrial KATP channels an overview of alternative mechanisms. J Mol Cell Cardiol 2005;39:17-50 (Pubitemid 40836043)
56. Mannhold R. KATP channel openers: structure-activity relationships and therapeutic potential. Med Res Rev 2004;24(2):213-266 (Pubitemid 38230680)
57. Simard JM, Chen M. Regulation by sulfanylurea receptor type 1 of a non-selective cation channel involved in cytotoxic edema of reactive astrocytes. J Neurosurg Anesthesiol 2004;16(1):98-99 (Pubitemid 38057409)
58. Simard JM, Woo SK, Bhatta S, Gerzanich V. Drugs acting on SUR1 to treat CNS ischemia and trauma. Curr Opin Pharmacol 2008;8(1):42-49 (Pubitemid 351168694)
59. Zeng J, Wang G, Chen SD. ATP-sensitive potassium channels: novel potential roles in Parkinson's disease. Neurosci Bull 2007;23(6):106-121
60. Wang L, Traystman RJ, Murphy SJ. Inhalation anesthetics as preconditioning agents in ischemic brain. Curr Opin Pharmacol 2008;8(1):104-110 (Pubitemid 351168690)
61. Clarkson AN. Anesthetic-mediated protection/preconditioning during cerebral ischemia. Life Sci 2007;80:1157-1175 (Pubitemid 46329012)
62. Yamada K, Inagaki N. Neuroprotection by KATP channels. J Mol Cell Cardiol 2005;38(6):945-949
63. Phillis JW. Adenosine and adenine nucleotides as regulators of cerebral blood flow: roles of acidosis, cell swelling, and KATP channels. Crit Rev Neurobiol 2004;16(4):237-270 (Pubitemid 40781082)
64. Burdakov D, Luckman DM, Verkhratsk A. Glucose-sensing neurons of the hypothalamus. Philos Trans R Soc Lond B Biol Sci 2005;360(1464):2227-2235 (Pubitemid 46682141)
65. Miki T, Seino S. Roles of KATP channels as metabolic sensors in acute metabolic changes. J Mol Cell Cardiol 2005;38(6):917-925 (Pubitemid 40725939)
66. Minami K, Miki T, Kadowaki T, Seino S. Roles of ATP-sensitive K+ channels as metabolic sensors: studies of Kir6.x null mice. Diabetes 2004;53(Suppl 3):S176-80 (Pubitemid 39564541)
67. Avshalumov MV, Bao L, Patel JC, Rice ME. H2O2 signaling in the nigrostriatal dopamine pathway via ATP-sensitive potassium channels: issues and answers. Antioxid Redox Signal 2007;9(2):219-231 (Pubitemid 46105421)
68. Sattiraju S, Reyes S, Kane GC, Terzic A. KATP channel pharmacogenomics: from bench to bedside. Clin Pharmacol Ther 2008;83(2):354-357
69. Nichols CG. KATP channels as molecular sensors of cellular metabolism. Nature 2006;440(7083):470-476
70. Matsuo M, Kimura Y, Ueda K. KATP channel interaction with adenine nucleotides. J Mol Cell Cardiol 2005;38(6):907-916 (Pubitemid 40725938)
71. Ballanyi K. Protective role of neuronal KATP channels in brain hypoxia. J Exp Biol 2004;207(Pt 18):3201-3212 (Pubitemid 39275294)
72. Lange M, Morelli A, Westphal M. Inhibition of potassium channels in critical illness. Curr Opin Anesthesiol 2008;21:105-110
73. Lange M, Morelli A, Ertmer C, et al. Role of adenosine triphosphate-sensitive potassium channel inhibition in shock states: physiology and clinical implications. Shock 2007;28(4):394-400 (Pubitemid 47415248)
74. Zünkler BJ. Human ether-a-go-go-related (HERG) gene and ATP-sensitive potassium channels as targets for adverse drug effects. Pharmacol Ther 2006;112(1):12-37 (Pubitemid 44339547)
75. Seino S, Miki T. Physiological and pathophysiological roles of ATP-sensitive K+ channels. Prog Biophys Mol Biol 2003;81:133-176 (Pubitemid 36141258)
76. Quayle JM, Nelson MT, Standen NB. ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol Rev 1997;77(4):1165-1232 (Pubitemid 27459582)
77. Lesage F, Guillemare E, Fink M, et al. TWIK-1, ubiquitous human weakly inward rectifying K+ channel with a novel structure. EMBO J 1996;15(5):1004-1011 (Pubitemid 26077828)
78. Lesage F, Reyes R, Fink M, et al. Dimerization of TWIK-1 K+ channel subunits via a disulfide bridge. EMBO J 1996;15(23):6400-6407 (Pubitemid 26413773)
79. Fink M, Duprat F, Lesage F, et al. Cloning, functional expression and brain localization of a novel unconventional outward rectifier K+ channel. EMBO J 1996;15(24):6854-6862 (Pubitemid 27023256)
80. Duprat F, Lesage F, Fink M, et al. TASK, a human background K+ channel to sense external pH variations near physiological pH. EMBO J 1997;16(17):5464- 5471 (Pubitemid 27380153)
81. Ketchum KA, Joiner WJ, Sellers AJ, et al. A new family of outwardly rectifying potassium channel proteins with two pore domains in tandem. Nature 1995;376:690-695
82. Zhou XL, Vaillant B, Loukin SH, et al. YKC1 encodes the depolarization-activated K+ channel in the plasma membrane of yeast. FEBS Lett 1995;373:170-176
83. Lesage F, Guillemare E, Fink M, et al. A pH-sensitive yeast outward rectifier K+ channels with two pore domains and novel gating properties. J Biol Chem 1996;271(8):4183-4187 (Pubitemid 26070519)
84. Fink M, Lesage F, Duprat F, et al. A neuronal two P domain K+ channel stimulated by arachidonic acid and polyunsaturated fatty acids. EMBO J 1998;17(12):3297-3308 (Pubitemid 28279504)
85. Lesage F, Lauritzen I, Duprat F, et al. The structure and distribution of the mouse TWIK-1 K+ channel. FEBS Lett 1997;402(1):28-32
86. Aller MI, Wisden W. Changes in expression of some two-pore domain potassium channel genes (KNCK) in selected brain regions of developing mice. Neurosci 2008;151:1154-1172
87. Kim D, Clapham DE. Potassium channels in cardiac cells activated by arachidonic acid and phospholipids. Science 1989;244:1174-1179
88. Rao VLR, Dhodda VK, Song G, et al. Traumatic brain injury-induced acute gene expression changes in rat cerebral cortex identified by GeneChip analysis. J Neurosci Res 2003;71(2):208-219 (Pubitemid 36055465)
89. Meuth SG, Kanyshkova T, Melzer N, et al. Altered neuronal expression if TASK1 and TASK3 potassium channels in rodent and human autoimmune CNS inflammation. Neurosci Lett 2008;446:133-138
90. Kim D, Sladek CD, Aguando-Velasco C, et al. Arachidonic acid activation of a new family of K+ channels in cultured rat neuronal cells. J Physiol (Lond) 1995;484:643-660
91. Lauritzen I, Blondeau N, Heurteaux C, et al. Polyunsaturated fatty acids are potent neuroprotectors. EMBO J 2000;19(8):1784-1793 (Pubitemid 30204390)
92. Plant LD, Kemp PJ, Peers C, et al. Hypoxia depolarization of cerebellar granule neurons by specific inhibition of TASK-1. Stroke 2002;33:2324-2328 (Pubitemid 35014650)
93. Miller P, Kemp PJ, Lewis A, et al. Acute hypoxia occludes hTREK-1 modulation: re-evaluation of the potential role of tandem P domain K+ channels in central neuroprotection. J Physiol (Lond) 2003;548(1):31-37 (Pubitemid 36410795)
94. Miller P, Peers C, Kemp PJ. Polymodal regulation of hTREK1 by pH, arachidonic acid, and hypoxia: physiological impact in acidosis and alkalosis. Am J Physiol Cell Physiol 2004;286:C272-82 (Pubitemid 38146351)
95. Xu X, Pan Y, Wang X. Alterations in the expression of lipid and mechano-gated two-pore domain potassium channel genes in rat brain following chronic cerebral ischemia. Brain Res Mol Brain Res 2004;120(2):205-209 (Pubitemid 38115820)
96. Li ZB, Zhang HX, Li LL, Wang XL. Enhanced expressions of arachidonic acid-sensitive tandem-pore domain potassium channels in rat experimental acute cerebral ischemia. Biochem Biophys Res Commun 2005;327(4):1163-1169 (Pubitemid 40137988)
97. Caley AJ, Gruss M, Franks NP. The effects of hypoxia on the modulation of human TREK-1 potassium channels. J Physiol (Lond) 2005;562(1):205-212 (Pubitemid 40207797)
98. Buckler KJ, Honoré E. The lipid-activated two-pore domain K+ channel TREK-1 is resistant to hypoxia: implication for ischaemic neuroprotection. J Physiol (Lond) 2005;562(1):213-222 (Pubitemid 40207798)
99. Heurteaux C, Laigle C, Blondeau N, et al. Alpha-linolenic acid and riluzole treatment confer cerebral protection and improve survival after focal brain ischemia. Neuroscience 2006;137(1):241-251 (Pubitemid 43031491)
100. Blondeau N, Pétrault O, Manta S, et al. Polyunsaturated fatty acids are cerebral vasodilators via the TREK-1 potassium channel. Circ Res 2007;101:176-184 (Pubitemid 47196585)
101. Hartness ME, Lewis A, Searle GJ, et al. Combined antisense and pharmacological approaches implicate hTASK as an airway O2 sensing K+ channels. J Biochem Chem 2001;276(28):26499-26508 (Pubitemid 37412871)
102. Lewis A, Hartness ME, Chapman CG, et al. Recombinant hTASK1 is an O2-sensitive K+ channel. Biochem Biophys Res Commun 2001;285:1290-1294
103. Campanucci VA, Brown ST, Judasek K, O'Kelly IM. O2 sensing by recombinant TWIK-related halothane-inhabitable K+ channel-1 background K+ channels heterologously expressed in human embryonic kidney cells. Neuroscience 2005;135(4):1087-1094 (Pubitemid 41416672)
104. Miller P, Kemp PJ, Peers C. Structural requirements for O2 sensing by the human tandem-P domain, hTREK1. Biochem Biophys Res Commun 2005;331:1253-1256 (Pubitemid 40692491)
105. Kim Y, Lee SH, Ho WK. Hydrogen peroxide selectively increases TREK-2 currents via myosin light chain kinases. Front Biosci 2007;12:1642-1650 (Pubitemid 46846796)
106. Heurteaux C, Guy N, Laigle C, et al. TREK-1, a K+ channel involved in neuroprotection and general anesthesia. EMBO J 2004;23:2684-2695 (Pubitemid 38988239)
107. Keshavaprasad B, Liu C, Au JD, et al. Species-specific differences in response to anesthetics and other modulators by the K2P channel TRESK. Anesth Analg 2005;101:1042-1049 (Pubitemid 41383070)
108. Linden AM, Aller MI, Leppä E, et al. The in vivo contributions of TASK-1-containing channels to the actions of inhalation anesthetics, the α2 adrenergic sedative dexmedetomidine, and cannabinoid agonists. J Pharmcol Exp Ther 2006;317(2):615-626
109. Kang D, Choe C, Kim D. Thermosensitivity of the two-pore domain K+ channels TREK-2 and TRAAK. J Physiol (Lond) 2005;564(1):103-116 (Pubitemid 40542191)
110. Maingret F, Patel AJ, Lesage F, et al. Mechano- or acid stimulation, two interactive modes of activation of the TREK-1 potassium channel. J Biochem Chem 1999;274(38):26691-26696 (Pubitemid 129520183)
111. Honoré E, Patel AJ, Chemin J, et al. Desensitization of mechano-gated K2P channels. Proc Natl Acad Sci 2006;103(18):6859-6864
112. Veale EL, Buswell R, Clarke CE, Mathie A. Identification of a region in the TASK3 two pore domain potassium channel that is critical for its blockade by methanandamide. Br J Pharmacol 2007;152:778-786 (Pubitemid 350034980)
113. Veale EL, Kennard LE, Sutton GL, et al. Gαq-mediated regulation of TASK3 two-pore domain potassium channels: the role of protein kinase C. Mol Pharmacol 2007;71:1666-1675 (Pubitemid 47010919)
114. Gierten J, Fickere E, Bloehs R, et al. Regulation of two-pore-domain (K2P) potassium leak channels by the tyrosine kinase inhibitor genistein. Br J Pharmacol 2008;154:1680-1690
115. Clarke CE, Veale EL, Wyse K, et al. The M1P1 loop of TASK3 K2P channels apposes the selectivity filter and influences channel function. J Biol Chem 2008;283(25):16985-16992
116. Lalevée N, Monier B, Sénatore S, et al. Control of cardiac rhythm by ORK1, a Drosophila two-pore domain potassium channel. Cur Biol 2007;16:1502-1508
117. Zhang C, Wang J, Wang GF, Su L. Relationship between TWIK-related acid-sensitive K+ channel-1 and TWIK-related acid-sensitive K+ channel-3 expression and the occurrence of central sleep apnea: experiment with rats. Zhonghua Yi Xue Za Zhi 2007;87(41):2929-2931 (in Chinese)
118. Inglis SK, Brown SG, Constable MJ, et al. A Ba2+-resistant, acid-sensitive K+ conductance in Na+-absorbing H441 human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2007;292:L1304-12
119. Lotshaw DP. Biophysical, pharmacological, and functional characteristics of cloned and native mammalian two-pore domain K+ channels. Cell Biochem Biophys 2007;47(2):209-256 (Pubitemid 47338363)
120. Kim D. Physiology and pharmacology of two-pore domain potassium channels. Curr Pharm Des 2005;11(21):2717-2736 (Pubitemid 41051880)
121. O'Connell AD, Morton MJ, Hunterm M. Two-pore domain K+ channels-molecular sensors. Biochim Biophys Acta 2002;1566:152-161
122. Honoré E. The neuronal background K2P channels: focus on TREK1. Nat Rev Neurosci 2007;8(4):251-261 (Pubitemid 46452327)
123. Mathie A. Neuronal tow-pore-domain potassium channels and their regulation by G protein-coupled receptors. J Physiol (Lond) 2007;578(Pt 2):377-385 (Pubitemid 46092203)
124. Plant LD, Rajan S, Goldstein SA. K2P channels and their protein partners. Curr Opin Neurobiol 2005;15(3):326-333 (Pubitemid 40806445)
125. Patel AJ, Honoré E. Properties and modulation of mammalian 2P domain K+ channels. Trends Neurosci 2001;24(6):339-346
126. Huang D, Yu B. Recent advance and possible future in TREK-2: a two-pore potassium channel may involved in the process of NPP, brain ischemia and memory impairment. Med Hypotheses 2008;70(3):618-624 (Pubitemid 351179897)
127. Duprat F, Lauritzen I, Patel A, Honoré E. The TASK background K2P channels: chemo- and nutrient sensors. Trends Neurosci 2007;30(11):573-580 (Pubitemid 350051422)
128. Uchino H, Morota S, Hirabayashi G, et al. Molecular mechanism of ischemic brain injuries and perspectives of drug therapies for neuroprotection. Masui 2007;56(3):248-270 (in Japanese)
129. Liu C, Cotton JF, Schuyler JA, et al. Protective effects of TASK-3 (KCNK9) and related 2P K channels during cellular stress. Brain Res 2005;1031(2):164-173 (Pubitemid 40093069)
130. Kindler CH, Yost CS. Two-pore domain potassium channels: new sites of local anesthetic action and toxicity. Reg Anesth Pain Med 2005;30(3):260-274 (Pubitemid 40718909)
131. Franks NP, Honoré E. The TREK K2P channels and their role in general anaesthesia and neuroprotection. Trends Pharmacol Sci 2004;25(11):601-608 (Pubitemid 39371151)
132. Mathie A, Sutton GL, Clarke CE, Veale EL. Zinc and copper: pharmacological probes and endogenous modulators of neuronal excitability. Pharmacol Ther 2006;111(3):567-583 (Pubitemid 44118429)
133. Bryan RM Jr, Joseph BK, Lloyd E, Rusch NJ. Starring TREK-1: the next generation of vascular K+ channels. Circ Res 2007;101:119-121 (Pubitemid 47196578)
134. Moudgil R, Michelakis ED, Archer SL. The role of K+ channels in determining pulmonary vascular tone, oxygen sensing, cell proliferation, and apoptosis: implications in hypoxic pulmonary vasoconstriction and pulmonary arterial hypertension. Microcirculation 2006;13(8):615-632 (Pubitemid 44696118)
135. Mathie A, Veale EL. Therapeutic potential of neuronal two-pore domain potassium-channel modulators. Curr Opin Investig Drugs 2007;8(7):555-562 (Pubitemid 47016323)
136. Kemp PJ, Peers C, Lewis A, Miller P. Regulation of recombinant human brain tandem P domain K+ channels by hypoxia: a role for O2 in the control of neuronal excitability? J Cell Mol Med 2004;8(1):38-44
137. Harald FMG. Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type 1, obesity and related conditions (in Chinese). CN101048153A; 2007
138. Cowen NM, Kashkin KB, Yamout KA. Salts of potassium ATP channel openers and uses thereof. EP1968601A2; 2008
139. Cowen NM, Kashkin KB. Pharmaceutical formulations of potassium ATP channels openers and uses thereof. JP2008510835T; 2008
140. Wu G. Method for decreasing blood glucose levels. US2007231273A1; 2007
141. Gehenne JNM, Allue M, Pugliese M. Compounds for the treatment of an acute injury to the central nervous system. JP2008503548T; 2008
142. Haikala H, Hyttila-Hopponem M, Nissinen E, et al. Anti-inflammatory agents. DE60110628T2; 2006
143. Horie S, Saito K, Ishizuka N. Therapeutic agents for overactive bladder. US2008033018A1; 2008
144. Jain N, Sui Z. Novel coumarin derivatives as ion channel openers. US20070037877A1; 2007;
145. Sui Z. Novel coumarin derivatives as ion channel openers. JP2008528495T; 2008
146. Jain N, Xu J, Sui Z. Novel pyridine derivatives as potassium channel openers. JP2008531592T; 2008
147. Jain N, Xu J, Sui Z. Novel quinoline derivatives as potassium ion channel openers. JP2008531590T; 2008
148. Zhang X, Li X, Sui Z. Novel benzopyran derivatives as potassium channel openers. US2007072832A1; 2007
149. Zhang X, Li X, Sui Z. Novel benzopyran derivatives as potassium channel openers. EP1937669A1; 2008
150. Hai W, Yonglin Y, Junhua J. Derivative of new benzothiadiazines, preparation method and usage (in Chinese). CN101092405A; 2007
151. Olesen IJ, Olesen J. Treatment of migraine and headaches. WO2007009462; 2007
152. Dahl BH, Christophersen P, Demnitz J. Diphenylurea derivatives useful as potassium channel activators. JP2008524158T; 2008
153. Hachtel S, Englert HC, Gerlach U, et al. Piperidinesulfonylureas and -thioureas, their preparation, their use and pharmaceutical compositions comprising them. US2008033016A1; 2008
154. Knieps S, Englert HC, Gerlach U, et al. Piperidinesulfonylureas and -thioureas, their preparation, their use and pharmaceutical compositions comprising them. JP2008524132T; 2008 (in German)
155. Antel J, Gregory PC, Lange JHM, et al. Use of CBX cannabinoid receptor modulators as potassium channel modulators. AR060626A1; 2008
156. Antel J, Gregory PC, Lange JHM, et al. Pharmaceutical compositions comprising CBX cannabinoid receptor modulators. WO2007125048A1; 2007
157. Johnson JD, Palma JF, Schweitzer AC, Blume JE. Methods and compositions for treating and diagnosing diabetes. US7053180B2; 2006
158. Aynsley-Green A, Lindley K, Docherty K, et al. Method of diagnosis. WO0190759A3; 2001
159. Ashcroft FM, Trapp S, Hiroshi S. KATP channel. WO0056887A1; 2000
160. Black KL, Ningaraj NS. Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor. JP2003523965T; 2003
161. Gehenne JNM, Rodriquez AMJ, Pugliese M. Compounds for the treatment of inflammation of the central nervous system. JP2008503549T; 2008
162. Salzman AL, Szabo C. Composition comprising a ATP channel inhibitor for use in the treatment of hemorrhagic shock. BR9710957A; 2001
163. Sugawara K, Tomita K, Kozlowski MR, Sawada Y. Compounds produced by a strain of Streptomyces exfoliates. US5332574A; 1994
164. Yokota M. Myocardial cell apoptosis inhibitors. EP1421952A4; 2005
165. Kim JJ, Moon DG. Pharmaceutical composition for preventing and treating sexual dysfunction. AR026506A1; 2003
166. Busija DW. Methods of protecting neuronal function. US6313112; 2001;
167. Busija D. Methods of protecting neuronal function. US6313112B1; 2001;
168. Cornell-Bell AH, Pemberton KE, Temple DL, et al. Uses of kappa-conotoxin PVIIA. US2004092447; 2004
169. Cornell-Bell AH, Pemberton KE, Temple DL, et al. Uses of kappa-conotoxin PVIIA. AU778182B2; 2004
170. Herlands L, Rossetti L, Pocai A. Intranasal administration of hypothalamic ATP-sensitive potassium channels. US2007026079A1; 2007
171. Herlands L, Pocai A, Rossetti L. Intranasal administration of hypothalamic ATP-sensitive potassium channels. WO2006088875A2; 2006
172. Terzic A, Olson TM, Kane GC. Diagnosing and treating potassium channel defects. US2006263805A1; 2006
173. Groppi VE Jr, Deibel MR Jr, Martin R Jr, et al. Protein affecting KATP channels. GR3035039T3; 2001
174. Kiyono S, Miki T, Oyama K. New application of genetically modified animal. JP2006149380A; 2006
175. Susumu S, Takashi M, Junichi M. ATP-sensitive potassium channel gene (Kir6.2/BIR)-deficient animals. DE69928996T2; 2006
176. Golz S, Brueggemeier ULF, Geerts A. Diagnostics and therapeutics for diseases associated with potassium channels, subfamily K, member 1 (KCNK1). WO2005054864A3; 2005
177. Curtis RAJ, Silos-Santiago I. Novel potassium channel molecules and uses therefore. WO0132872A3; 2001
178. Francis-Lang HL, Gillett LA, Margolis JS, et al. Nucleic acids and polypeptides of invertebrate TWIK channels and methods of use. WO0109301A3; 2001
179. Buchman AR, Burks C, Francis-Lang HL, et al. Nucleic acids and polypeptides of invertebrate TWIK channels and methods of use. US6703491B1; 2004
180. Lesage F, Guillemare E, Fink M, et al. Isolated TWIK-1 potassium channel proteins. US7067625B1; 2006
181. Lesage F, Guillemare E, Fink M, et al. Nucleic acid encoding new potassium channel designated TWIK-1. EP0799889B1; 2004
182. Ellinghaus P, Munter K. Modulators of the potassium channels twik-1, task-1, gorl1, sk2 pr pcn1, used to treat arrhythmia, coronary heart disease or hypertension. US2006183665A1; 2006
183. Meadows HJ, Chapman CG. TREK-1 like two pore potassium channels. JP2002511233T; 2002
184. Meadows HJ, Chapman CG. TREK-1 like two pore potassium channels. EP1051485A1; 2000
185. Hervieu GJ, Meadows HJ, Randall AD. New use. EP1187627B1; 2003
186. Golz S, Brueggemeier UFL, Geerts A. Diagnostics and therapeutics for diseases associated with two-pore domain potassium channel (KCN2). WO2005054866A3; 2005
187. Lazdunski M, Honoré E, Lesage F, et al. A method for the identification of anesthetics. JP2002536017T; 2002
188. Saint DA, Zhu H. Potassium channels in human heart. WO2006066334A1; 2006
189. Patel AJ, Honoré E, Lesage F, et al. Method for the identification of anesthetics. US7112403B1; 2006
190. Feinmark SJ, Robinson RB. Method of treating a condition associated with phosphorylation of TASK-1. WO2008013988A9; 2008
191. Robinson RB, Feinmark SJ. Method of treating a condition associated with phosphorylation of TASK-1. WO2007014347A9; 2007
192. Golz S, Brueggemeier ULF, Geerts A. Diagnostics and therapeutics for diseases associated with potassium channel, subfamily K, member 3 (KCNK3). WO2005052586A3; 2005
193. Duprat F, Lesage F, Fink M, Lazdunski M. Family of mammalian potassium channels, their cloning and their use, especially for the screening of drugs. US6309855B1; 2001
194. Chissoe S. Genes associated with COPD. US2008108079A1; 2008
195. Honoré E, Fink M, Lazdunski M, et al. Method for screening substances capable of modulating the activity of a TRAAK potassium channel. US2006024729A1; 2006
196. Lazdunski M, Lesage F, Maingret F. Family of mechanosensitive human channels activated by polyunsaturated fatty acids. US2003049697A1; 2003
197. Golz S, Brueggemeier ULF, Geerts A. Diagnostics and therapeutics for diseases associated with potassium channels, subfamily K, member 4 (KCNK4). WO2005052574A3; 2005
198. Chapman CG, Duckworth DM. Human potassium channel (h-TRAAK). US6426197B1; 2002
199. Duckworth DM, Chapman CG. Polynucleotides encoding a human potassium channel. US6426197B1; 2002
200. Pausch MH, Price LA. Potassium channels, nucleotide sequences encoding them, and methods of using same. US2006110792A1; 2006
201. Pausch MH. Potassium channels, nucleotide sequences encoding them, and methods of using. US2003165806A1; 2003
202. Lazdunski M, Guy N. Method for identifying antidepressants, based on ability of test compounds to inhibit potassium channels that contain two pore domains, also use of antibodies against these channels for treating depression. FR2850397A1; 2004
203. Curtis RAJ, Glucksmann MA, Silos-Santiago I. Novel TWIK-6, TWIK-7, IC23927, TWIK-8, IC47611, IC46715, HNMDA-1, TWIK-9, alpha2delta-4, 8099, 46455, 54414, 53763, 97076, 97102, 44181, 67084FI and 67084alt molecules and uses therefore. US2008032289A1; 2008
204. Curtis RAJ. 56115, a novel human TWIK potassium channel and uses therefore. WO0226983A3; 2002
205. Curtis RAJ, Silos-Santiago I. TWIK-5 potassium polypeptides and uses therefore. US6664373B1; 2003
206. Curtis RAJ. TWIK-5 potassium nucleic acids and uses therefore. US6670149B1; 2003
207. Glucksmann A. 12303, a novel human TWIK molecule and uses therefore. DE60124910T2; 2007
208. Partiseti M. Two P domains potassium channel. WO9936529A2; 1999
209. Lazdunski M, Lesage F, Romey G. Human TREK2, a stretch- and arachidonic acid-sensitive K+ channel activated by inhalational anesthetics and riluzole. US6962976B2; 2005
210. Chapman CG, Duckworth DM. Human TREK2 polypeptides. GB2365010A; 2002.